Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Microbiol.

Sec. Microorganisms in Vertebrate Digestive Systems

This article is part of the Research TopicThe Role of Gut Microbes and Their Metabolites in Metabolic Diseases: Mechanisms and Therapeutic TargetsView all 32 articles

Nitrogen recycling by the gut microbiome in sarcopenia

Provisionally accepted
Rosa  HallerRosa Haller1,2Olha  HaziaOlha Hazia1,2Nicole  FeldbacherNicole Feldbacher1,2Julia  TraubJulia Traub3Tobias  MadlTobias Madl4,5Hansjörg  HabischHansjörg Habisch4Angela  HorvathAngela Horvath1,2Vanessa  StadlbauerVanessa Stadlbauer1,2,5*
  • 1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medizinische Universitat Graz, Graz, Austria
  • 2CBmed GmbH, Graz, Austria
  • 3Department of Clinical Medical Nutrition, Landeskrankenhaus-Universitatsklinikum Graz, Graz, Austria
  • 4Otto Loewi Research Center, Medicinal Chemistry, Medizinische Universitat Graz, Graz, Austria
  • 5BioTechMed-Graz Geschaftsstelle, Graz, Austria

The final, formatted version of the article will be published soon.

Sarcopenia, defined as loss of skeletal muscle mass and strength, affects up to 70% of patients with liver cirrhosis. Since hibernating animals maintain muscle mass through microbial nitrogen recycling, urease-producing bacteria may have a protective role in humans. We hypothesized that altered microbial urease abundance contributes to differences in nitrogen recycling potential between patients with and without sarcopenia, with sex-specific effects. Stool samples from 152 patients with (n=101) and without sarcopenia (n=51) were analyzed. Functional profiles were predicted from 16S rRNA gene amplicon sequencing data using Tax4Fun2, and predicted abundances of urease subunit alpha were extracted. A systematic literature search identified 120 urease-producing taxa, of which 35 were represented in sequencing data. Sarcopenia is associated with a lower predicted abundance of urease subunit alpha in patients with cirrhosis (n=96; p=0.045, r=0.20; median=0.0002 vs. 0.0004), irrespective of sex, and in women (n=49, p=0.037, r=0.30, median=0.0002 vs. 0.0004), irrespective of cirrhosis. Urease subunit alpha abundance increases with the use of proton pump inhibitors (PPI) in the entire patient cohort (p=0.0028, r =0.24, median=0.0003 vs. 0.0002), patients with cirrhosis (p=0.033, r=0.22, median=0.0004 vs. 0.0002), and men (n=103, p=0.0005, r =0.34, median=0.0002 vs. 0.0001). Beta-blockers are associated with higher urease subunit alpha abundance in the entire patient cohort (p=0.018, r=0.19, median=0.0003 vs. 0.0002) and women (p=0.031, r=0.31, median=0.0004 vs. 0.0002). The overall abundance of potentially urease-producing taxa was comparable between the groups. The increased urease subunit alpha abundance in patients without sarcopenia, but with cirrhosis, and women, and the influence of medication on the abundance point towards potential additional effects of beta-blockers in sarcopenia.

Keywords: cirrhosis, Sarcopenia, gut microbiome, Urease, Nitrogen recycling, Host-microbiome interaction

Received: 03 Sep 2025; Accepted: 18 Nov 2025.

Copyright: © 2025 Haller, Hazia, Feldbacher, Traub, Madl, Habisch, Horvath and Stadlbauer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Vanessa Stadlbauer, vanessa.stadlbauer@medunigraz.at

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.